UNSPSC 51321801: Ponfibrate

This classification denotes an anti-lipidemic agent with the molecular formula C18H16Cl2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0ARR2L0V0A, chemically known as 12h-dibenzo(d,g)(1,3)dioxocin-6-carboxylic acid, 2,10-dichloro-12-methyl-, ethyl ester, trans- but generally known as ponfibrate, which bears US NIH Compound Identifier 68701. European Medicines Agency schedules Ponfibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09979MIG.

UNSPSC 51321801 Ponfibrate is a Commodity code under which state and local governments procure specific pharmaceutical products for emergency medical services, health benefit programs, and institutional healthcare delivery. Recent solicitations reveal that buyers use this code to source individual medication line items—including vasodilators, adrenergic agents, and cardiac medications—for emergency response fleets, state pharmacy benefit programs, and multi-jurisdictional cooperative purchasing arrangements. The code spans sealed competitive bidding for immediate-need medications, exploratory RFIs for direct-to-manufacturer relationships, and cooperative purchasing RFPs that consolidate demand across multiple state and local member agencies. Issuing bodies include city purchasing departments managing fire rescue operations, state health and human services agencies overseeing pharmacy benefit design, and multi-state cooperative purchasing alliances coordinating procurement for participating jurisdictions.

Activity under this code is concentrated in Florida and Texas, with multi-state cooperative procurement extending through Minnesota and Oregon. The City of Tampa's Purchasing Department posted an IFB (Solicitation 26P00188) on April 24, 2026, seeking sealed bids for Advanced Life Support Medications—including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem—with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted an RFP (S1070000015802) on January 20, 2026 with a response deadline of March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed through authorized wholesalers across participating states including Oregon, with contract effectiveness set for July 1, 2026. Set-asides appear in the Tampa solicitation under a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount not to exceed $10,000.